Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EBT (2016 - 2025)

Historic EBT for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$27.8 million.

  • Voyager Therapeutics' EBT fell 20895.46% to -$27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.1 million, marking a year-over-year decrease of 57068.29%. This contributed to the annual value of -$64.3 million for FY2024, which is 14810.67% down from last year.
  • Voyager Therapeutics' EBT amounted to -$27.8 million in Q3 2025, which was down 20895.46% from -$33.4 million recorded in Q2 2025.
  • Voyager Therapeutics' 5-year EBT high stood at $124.7 million for Q1 2023, and its period low was -$33.9 million during Q4 2024.
  • In the last 5 years, Voyager Therapeutics' EBT had a median value of -$22.1 million in 2023 and averaged -$7.5 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 56669.3% in 2022, then surged by 68514.94% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' EBT stood at $5.1 million in 2021, then plummeted by 566.69% to -$23.6 million in 2022, then skyrocketed by 342.34% to $57.2 million in 2023, then tumbled by 159.25% to -$33.9 million in 2024, then rose by 17.97% to -$27.8 million in 2025.
  • Its EBT was -$27.8 million in Q3 2025, compared to -$33.4 million in Q2 2025 and -$31.0 million in Q1 2025.